Adjusted EBITDA was positive $12.5 million, improving by nearly $13 million compared to the prior year.
Gross margin was 82% for the quarter, slightly below Q1 due to nonroutine expenses related to Gvoke capacity expansion.
Gvoke revenue increased 17% to $23.5 million, supported by a 5% growth in total prescriptions and favorable gross-to-net adjustments.
Keveyis revenue rose modestly to $11.5 million, with a slight increase in patient numbers and new patient starts.
R&D expenses increased by $2.2 million to $8.1 million, reflecting investments in pipeline products including XP-8121.
Recorlev revenue surged 136% year-over-year to $31.4 million, with a 122% increase in the average number of patients on therapy.
SG&A expenses rose 11% year-over-year to $44.4 million, mainly due to Recorlev commercial expansion and personnel costs.
Xeris Biopharma reported a 49% year-over-year increase in total revenue to $71.5 million in Q2 2025, driven by a 46% increase in net product revenue to $67.7 million.
AGAMREE net product revenue reached $27.4 million in Q2 2025, a 213% increase year-over-year, with first half revenues up 398%.
Cash and cash equivalents increased to $652.8 million at June 30, 2025, up from $517.6 million at December 31, 2024.
Catalyst Pharmaceuticals reported Q2 2025 total revenue of $146.6 million, a 19.4% increase year-over-year.
FYCOMPA revenue was $34.3 million in Q2 2025, down 6% year-over-year, with first half revenue up 4.5%.
GAAP net income for Q2 2025 was $52.1 million or $0.41 per diluted share, a 27.7% increase year-over-year.
Net product revenue for FIRDAPSE was $84.8 million in Q2 2025, up 9.7% year-over-year, with a 16.9% increase for the first half of 2025 compared to 2024.
Non-GAAP net income was $86.4 million or $0.68 per diluted share, up from $69.6 million or $0.56 per diluted share in Q2 2024.
Dafinchi
